Mood & Emotion (우울조울병)

Korean Society for Affective Disorders (대한우울조울병학회)
권호 표지

Comparison of the Bupropion versus Aripiprazole Adjunctive Therapy for the Treatment of Female Depression : Post-Hoc Analyses from a Randomized Prospective Open-Label Multi-Center Study

여성 우울증 환자에서 Aripiprazole과 Bupropion 부가요법의 우울증상 및 안전성에 대한 효과 비교 : 사후분석연구

  • Keum, Mu-sung (Department of Psychiatry, Yeungnam University College of Medicine, Yeungnam University Medical Center) ;
  • Cheon, Eun-Jin (Department of Psychiatry, Yeungnam University College of Medicine, Yeungnam University Medical Center) ;
  • Lee, Kwang-Hun (Department of Neuropsychiatry, Dongguk University Kyungju Hospital) ;
  • Koo, Bon-Hoon (Department of Psychiatry, Yeungnam University College of Medicine, Yeungnam University Medical Center) ;
  • Lee, Young-Ji (Department of Psychiatry, Yeungnam University College of Medicine, Yeungnam University Medical Center) ;
  • Park, Young-Woo (Department of Neuropsychiatry, Daegu Fatima Hospital) ;
  • Lee, Jong-hun (Department of Psychiatry, Catholic University of Daegu School of Medicine) ;
  • Lee, Seung-Jae (Department of Psychiatry, Kyungpook National University School of Medicine) ;
  • Sung, Hyung-Mo (Department of Neuropsychiatry, College of Medicine, Pochon Cha University, Cha Hospital)
  • 금무성 (영남대학교 의과대학 정신건강의학교실) ;
  • 천은진 (영남대학교 의과대학 정신건강의학교실) ;
  • 이광헌 (동국대학교 의과대학 경주병원 정신건강의학교실) ;
  • 구본훈 (영남대학교 의과대학 정신건강의학교실) ;
  • 이영지 (영남대학교 의과대학 정신건강의학교실) ;
  • 박영우 (대구파티마병원 정신건강의학과) ;
  • 이종훈 (대구가톨릭대학교 의과대학 정신건강의학교실) ;
  • 이승재 (경북대학교 의학전문대학원 정신건강의학교실) ;
  • 성형모 (CHA의과학대학교 구미차병원 정신건강의학교실)
  • Received : 2018.07.05
  • Accepted : 2018.08.13
  • Published : 2018.11.30

⟨ Previous Next ⟩

Abstract

Objectives : The purpose of this study was to examine effects of adjunctive aripiprazole versus bupropion, on depressive symptoms of female depression. Methods : Sixty six female patients with major depressive disorders were enrolled from a six-week, randomized prospective open-label multi-center study. Participants were randomized to receive aripiprazole (2.5-10 mg/day) or bupropion (150-300 mg/day). Montgomery Asberg Depression Rating Scale, 17-item Hamilton Depression Rating scale (HAM-D17), Iowa Fatigue Scale, Drug-Induced Extrapyramidal Symptoms Scale, Psychotropic-Related Sexual Dysfunction Questionnaire scores, and Clinical Global Impression-Severity (CGI-S) were obtained at baseline and after one, two, four, and six weeks. Changes on individual items of HAM-D17 were assessed as well as on composite scales (anxiety, insomnia and drive), and on four core subscales that capture core depression symptoms. Results : Overall, both treatments improved depressive symptoms, without causing serious adverse events. There were significant differences in the HAM-D17 total score (p=0.046) and CGI-S (p=0.004), between aripiprazole and bupropion augmentation, favoring aripiprazole over bupropion. Aripiprazole revealed significantly greater effect size in depressed mood (p=0.006), retardation (p=0.005), anxiety psychic (p=0.032), and general somatic symptom (p=0.01). Conclusion : While both treatments were effective, results of this study suggested that aripiprazole may be preferable, in treating general and core symptoms of female depression.

Keywords

Acknowledgement

Supported by : 오츠카제약주식회사

References

  1. Weissman MM, Bland R, Joyce PR, Newman S, Wells JE, Wittchen HU. Sex differences in rates of depression: cross-national perspectives. J Affect Disord 1993;29:77-84. https://doi.org/10.1016/0165-0327(93)90025-F
  2. Bijl RV, De Graaf R, Ravelli A, Smit F, Vollebergh WA, Netherlands Mental Health S, et al. Gender and age-specific first incidence of DSM-III-R psychiatric disorders in the general population. Results from the Netherlands Mental Health Survey and Incidence Study (NEMESIS). Soc Psychiatry Psychiatr Epidemiol 2002;37:372-379. https://doi.org/10.1007/s00127-002-0566-3
  3. Oldehinkel AJ, Bouma EM. Sensitivity to the depressogenic effect of stress and HPA-axis reactivity in adolescence: a review of gender differences. Neurosci Biobehav Rev 2011;35:1757-1770. https://doi.org/10.1016/j.neubiorev.2010.10.013
  4. Schuch JJ, Roest AM, Nolen WA, Penninx BW, de Jonge P. Gender differences in major depressive disorder: results from the Netherlands study of depression and anxiety. J Affect Disord 2014;156:156-163. https://doi.org/10.1016/j.jad.2013.12.011
  5. Silverstein B, Patel P. Poor response to antidepressant medication of patients with depression accompanied by somatic symptomatology in the STAR*D Study. Psychiatry Res 2011;187:121-124. https://doi.org/10.1016/j.psychres.2010.12.026
  6. Mischoulon D, Nierenberg AA, Kizilbash L, Rosenbaum JF, Fava M. Strategies for managing depression refractory to selective serotonin reuptake inhibitor treatment: a survey of clinicians. Can J Psychiatry 2000;45:476-481. https://doi.org/10.1177/070674370004500509
  7. Berman RM, Fava M, Thase ME, Trivedi MH, Swanink R, Mc-Quade RD, et al. Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants. CNS Spectr 2009;14:197-206. https://doi.org/10.1017/S1092852900020216
  8. Fava M. Diagnosis and definition of treatment-resistant depression. Biol Psychiatry 2003;53:649-659. https://doi.org/10.1016/S0006-3223(03)00231-2
  9. Cheon EJ, Lee KH, Park YW, Lee JH, Koo BH, Lee SJ, et al. Comparison of the Efficacy and Safety of Aripiprazole Versus Bupropion Augmentation in Patients With Major Depressive Disorder Unresponsive to Selective Serotonin Reuptake Inhibitors: A Randomized, Prospective, Open-Label Study. J Clin Psychopharmacol 2017;37:193-199. https://doi.org/10.1097/JCP.0000000000000663
  10. Nelson JC, Mankoski R, Baker RA, Carlson BX, Eudicone JM, Pikalov A, et al. Effects of aripiprazole adjunctive to standard antidepressant treatment on the core symptoms of depression: a post-hoc, pooled analysis of two large, placebo-controlled studies. J Affect Disord 2010;120:133-140. https://doi.org/10.1016/j.jad.2009.06.026
  11. Jocob Cohen. Statistical power analysis for the behavioral sciences. Lawrence Earlbaum Associates 1988;Hillsdale:20-26.
  12. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62. https://doi.org/10.1136/jnnp.23.1.56
  13. Yi JS, Bae SO, Ahn YM, Park DB, Noh KS, Shin HK, et al. Validity and Reliability of the Korean Version of the Hamilton Depression Rating Scale(K-HDRS). J Korean Neuropsychiatr Assoc 2005;2005; 44:456-465.
  14. Bech P, Gram LF, Dein E, Jacobsen O, Vitger J, Bolwig TG. Quantitative rating of depressive states. Acta Psychiatr Scand 1975;51:161-170. https://doi.org/10.1111/j.1600-0447.1975.tb00002.x
  15. Maier W, Philipp, M. Improving the assessment of severity of depressive states: a reduction of the Hamilton Depression Scale. Pharmacopsychiatry 1985;18:114-115. https://doi.org/10.1055/s-2007-1017335
  16. Gibbons RD DCC, Kupfer DJ. Exactly what does the Hamilton depression rating scale measure? Journal of Psychiatric Research 1993;27:259-273. https://doi.org/10.1016/0022-3956(93)90037-3
  17. Evans KR, Sills T, DeBrota DJ, Gelwicks S, Engelhardt N, Santor D. An Item Response analysis of the Hamilton Depression Rating Scale using shared data from two pharmaceutical companies. J Psychiatr Res 2004;38:275-284. https://doi.org/10.1016/j.jpsychires.2003.11.003
  18. Marcus RN, McQuade RD, Carson WH, Hennicken D, Fava M, Simon JS, et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol 2008;28:156-165. https://doi.org/10.1097/JCP.0b013e31816774f9
  19. Stahl SM, Pradko JF, Haight BR, Modell JG, Rockett CB, Learned-Coughlin S. A Review of the Neuropharmacology of Bupropion, a Dual Norepinephrine and Dopamine Reuptake Inhibitor. Prim Care Companion J Clin Psychiatry 2004;6:159-166. https://doi.org/10.4088/PCC.v06n0403
  20. Nasr S, Wendt B, Popli A, Crayton J. Comparing outcomes of adjunctive treatment in depression: aripiprazole versus bupropion. J Affect Disord 2014;162:50-54. https://doi.org/10.1016/j.jad.2014.03.019
  21. Leggio GM, Salomone S, Bucolo C, Platania C, Micale V, Caraci F, et al. Dopamine D(3) receptor as a new pharmacological target for the treatment of depression. Eur J Pharmacol 2013;719:25-33. https://doi.org/10.1016/j.ejphar.2013.07.022
  22. Naber D, Lambert M. Aripiprazole: a new atypical antipsychotic with a different pharmacological mechanism. Prog Neuropsychopharmacol Biol Psychiatry 2004;28:1213-1219. https://doi.org/10.1016/j.pnpbp.2004.06.020
  23. Mathew SJ, Manji HK, Charney DS. Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology 2008;33:2080-2092. https://doi.org/10.1038/sj.npp.1301652
  24. DeLeon A, Patel NC, Crismon ML. Aripiprazole: a comprehensive review of its pharmacology, clinical efficacy, and tolerability. Clin Ther 2004;26:649-666. https://doi.org/10.1016/S0149-2918(04)90066-5
  25. Nagoshi Y, Tominaga T, Fukui K. Effect of aripiprazole augmentation for treatment-resistant somatoform disorder: a case series. J Clin Psychopharmacol 2014;34:397-398. https://doi.org/10.1097/JCP.0000000000000063
  26. Clayton AH. The pathophysiology of hypoactive sexual desire disorder in women. Int J Gynaecol Obstet 2010;110:7-11. https://doi.org/10.1016/j.ijgo.2010.02.014